Medications

Q&A: Experts discuss pros, cons of new Alzheimer's drug

Patient care teams are preparing to offer lecanemab, a new Alzheimer's disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.

Health

Intranasal insulin may have pro-cognitive benefits

Intranasal insulin (INI) seems to have a beneficial effect on global cognition among patients with Alzheimer's disease (AD)/mild cognitive impairment (MCI), according to a review published online June 28 in PLOS ONE.

page 7 from 40